EPIBX Performance — EuroPac International Bond Fund, Class A
Data updated: 2026-09-28
EPIBX returned +0.30% year to date and +4.53% over one year to Jul 2026. Annualised returns are +3.75% over 3 years and +1.79% over 5 years. The fund trailed its International Short-Term Core Bond category average: $100 invested three years ago grew to $112, against $119 for the category, and to $105 over one year, against $105. Volatility over the past three years was 6.32% a year. In the 12 months to Jul 2026 the fund took in a net $31.0M, and assets reached $96.23M.
EPIBX Growth of $100
What $100 invested in EuroPac International Bond Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the International Short-Term Core Bond category average over the same months.
| Period | EPIBX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $105 | $105 |
| 3 years (Aug 2023 – Jul 2026) | $112 | $119 |
| 5 years (Aug 2021 – Jul 2026) | $109 | $112 |
| Since data start (Feb 2020 – Jul 2026) | $114 | $117 |
EPIBX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +0.30% |
| 1 year | +4.53% |
| 3 years (annualised) | +3.75% |
| 5 years (annualised) | +1.79% |
EPIBX Annual Returns
Calendar-year total returns of EuroPac International Bond Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +0.30% |
| 2025 | +12.89% |
| 2024 | −3.30% |
| 2023 | +9.94% |
| 2022 | −7.34% |
| 2021 | −4.60% |
| 2020 (Feb–Dec) | +7.32% |
EPIBX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.5% | +0.7% | −3.7% | +1.8% | +0.2% | −0.7% | +0.8% | — | — | — | — | — |
| 2025 | +1.0% | +0.7% | +2.4% | +2.4% | +0.8% | +2.4% | −1.6% | +2.0% | +0.8% | −0.2% | +1.0% | +0.5% |
| 2024 | −1.3% | +0.2% | +0.7% | −2.3% | +1.8% | −1.9% | +0.8% | +2.1% | +1.8% | −2.9% | −0.7% | −1.6% |
| 2023 | +2.8% | −1.8% | +2.3% | +0.7% | −1.0% | +2.5% | +2.0% | −2.2% | −2.0% | −1.0% | +4.5% | +2.8% |
| 2022 | −1.3% | −0.2% | +0.1% | −4.3% | +1.5% | −3.8% | +1.0% | −1.7% | −4.1% | +0.9% | +4.3% | +0.5% |
| 2021 | −0.8% | −1.5% | −1.1% | +1.4% | +1.1% | −1.3% | −0.3% | +0.1% | −1.9% | +0.5% | −2.2% | +1.5% |
| 2020 | — | −1.5% | −6.8% | +3.9% | +1.9% | +1.4% | +2.9% | +1.1% | −1.6% | +0.2% | +3.5% | +2.4% |
EPIBX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 6.32%
- 3-year Sharpe ratio: -0.12 (vs 4.5% risk-free rate)
- Best month: +4.47% (Nov 2023)
- Worst month: −3.73% (Mar 2026)
EPIBX Fund Flows
Monthly money in and out of EuroPac International Bond Fund, from SEC Form N-PORT.
- 12-month net flow: $31.0M
- 12-month gross sales (incl. reinvestments): $49.0M
- Sales ÷ redemptions: 2.72×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $3.9M | $1.0M | $2.8M |
| Jun 2026 | $4.6M | $670K | $3.9M |
| May 2026 | $4.6M | $1.1M | $3.5M |
| Apr 2026 | $7.2M | $1.1M | $6.1M |
| Mar 2026 | $9.7M | $2.0M | $7.7M |
| Feb 2026 | $3.6M | $4.2M | −$649K |
| Jan 2026 | $3.7M | $1.5M | $2.2M |
| Dec 2025 | $3.9M | $1.6M | $2.3M |
| Nov 2025 | $1.2M | $620K | $556K |
| Oct 2025 | $2.1M | $968K | $1.2M |
| Sep 2025 | $1.8M | $958K | $802K |
| Aug 2025 | $2.8M | $2.3M | $545K |
EPIBX Assets Under Management
Net assets of EuroPac International Bond Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $96.23M |
| 2026-04-30 | $86.99M |
| 2026-01-31 | $75.14M |
| 2025-10-31 | $69.76M |
| 2025-07-31 | $65.94M |
| 2025-04-30 | $56.85M |
| 2025-01-31 | $51.37M |
| 2024-10-31 | $55.16M |
| 2024-07-31 | $55.39M |
| 2024-04-30 | $57.07M |
| 2024-01-31 | $59.63M |
| 2023-10-31 | $55.39M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.